The use of peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 8, 2012, Pages 1013-1016

  Nunnari, G ^a   MOntineri, A ^b   Portelli, V ^c   Savalli, F ^c   Fatuzzo, F ^b   Cacopardo, B ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Ferrarotto Hospital   (Italy)

^c S Antonio Hospital   (Italy)

Author keywords

Acute Hepatitis C; HCV; Peginterferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS C ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; DRUG USE; FEMALE; GENOTYPING TECHNIQUE; HEPATITIS C; HUMAN; LIVER BIOPSY; MALE; MONOTHERAPY; REVIEW; RISK FACTOR; SEROCONVERSION; SEXUALLY TRANSMITTED DISEASE; SURGERY; TATTOO; TREATMENT RESPONSE; VIRAL CLEARANCE; ACUTE DISEASE; ARTICLE; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; VIROLOGY;

ACUTE DISEASE; ADULT; ALANINE TRANSAMINASE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN;

EID: 84865827157     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. GUADAGNINO V, STROFFOLINI T, RAPICETTA M, COSTANTINO A, KONDILI LA, MENNITI-IPPOLITO F, CAROLEO B, COSTA C, GRIFFO G, LOIACONO L, PISANI V, FOCÀ A,PIAZZA M. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community-based survey in southern Italy. Hepatology 1997; 26: 1006-1011.
2. LIANG TJ, REHERMANN B, SEEFF LB, HOOFNAGLE JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305.
3. WASLEY A, ALTER MJ. Epidemiology of hepatitis C: Geographic differences and temporal trends. Semin Liver Dis 2000; 20: 1-16.
4. GERLACH JT, DIEPOLDER HM, ZACHOVAL R, GRUENER NH, JUNG MC, ULSENHEIMER A, SCHRAUT WW, SCHIRREN CA, WAECHTLER M, BACKMUND M, PAPE GR. Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80-88.
5. MOSLEY JW, OPERSKALSKI EA, TOBLER LH, ANDREWS WW, PHELPS B, DOCKTER J, GIACHETTI C, BUSCH MP. Viral and host factors in early hepatitis C virus infection. Hepatology 2005; 42: 86-92.
6. FARCI P, SHIMODA A, COIANA A, DIAZ G, PEDDIS G, MELPOLDER JC, STRAZZERA A,CHIEN DY, MUNOZ SJ, BALESTRIERI A, PURCELL RH, ALTER HJ. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288(5464): 339-344.
7. HWANG SJ, LEE SD, LU RH, CHU CW, WU JC, LAI ST, CHANG FY. Hepatitis C viral genotype influences the clinical outcome of patients with acute posttransfusion hepatitis C. J Med Virol 2001; 65: 505-509.
8. LEHMANN M, MEYER MF, MONAZAHIAN M, TILLMANN HL, MANNS MP, WEDEMEYER H. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol 2004; 73: 387-391.
9. JAECKEL E, CORNBERG M, WEDEMEYER H, SANTANTONIO T, MAYER J, ZANKEL M, PASTORE G, DIETRICH M, TRAUTWEIN C, MANNS MP; GERMAN ACUTE HEPATITIS C THERAPY GROUP. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-1457.
10. SANTANTONIO T, FASANO M, SINISI E, GUASTADISEGNI A, CASALINO C, MAZZOLA M, FRANCAVILLA R, PASTORE G. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005; 42: 329-333.
11. WIEGAND J, BUGGISCH P, BOECHER W, ZEUZEM S, GELBMANN CM, BERG T, KAUFFMANN W, KALLINOWSKI B, CORNBERG M, JAECKEL E, WEDEMEYER H, MANNS MP; GERMAN HEP-NET ACUTE HCV STUDY GROUP. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEPNET acute-HCV-II study. Hepatology 2006; 43: 250-256.
12. KAMAL SM, FOULY AE, KAMEL RR, HOCKENJOS B, AL TAWIL A, KHALIFA KE, HE Q, KOZIEL MJ, EL NAGGAR KM, RASENACK J, AFDHAL NH. Peginterferon alfa-2b therapy in acute hepatitis C: Impact of onset of therapy on sustained virologic response. Gastroenterology 2006; 130: 632-638. Erratum in: Gastroenterology 2006; 131: 979.
13. GILLEECE YC, BROWNE RE, ASBOE D, ATKINS M, MANDALIA S, BOWER M, GAZZARD BG, NELSON MR. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 2005; 40: 41-46.
14. ROCCA P, BAILLY F, CHEVALLIER M, CHEVALLIER P, ZOULIM F, TRÉPO C. Early treatment of acute hepatitis C with interferon alpha-2b or interferon alpha-2b plus ribavirin: Study of sixteen patients. Gastroenterol Clin Biol 2003; 27(3 Pt 1): 294-299.
15. LICATA A, DI BONA D, SCHEPIS F, SHAHIED L, CRAXÍ A, CAMMÀ C. When and how to treat acute hepatitis C? J Hepatol 2003; 39: 1056-1062.
16. MAHESHWARI A, THULUVATH PJ. Management of acute hepatitis C. Clin Liver Dis 2010; 14: 169-176.
17. COREY KE, MENDEZ-NAVARRO J, GOROSPE EC, ZHENG H, CHUNG RT. Early treatment improves outcomes in acute hepatitis C virus infection: A meta-analysis. J Viral Hepat 2010; 17: 201-207.
18. PALUMBO E. PEG-interferon in acute and chronic hepatitis C: A review. Am J Ther 2009; 16: 573-578.
19. GHANY MG, STRADER DB, THOMAS DL, SEEFF LB; AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009; 49: 1335-1374.